CASTLE BIOSCIENCES INC — Director's Dealing 2021

Sep 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CASTLE BIOSCIENCES INC (CSTL)
CIK: 0001447362
Period of Report: 2021-09-02

Reporting Person: Spiess Bernhard E. (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-02	Common Stock	M	8989	$1.92	Acquired	22551	Direct
2021-09-02	Common Stock	M	6412	$2.39	Acquired	28963	Direct
2021-09-02	Common Stock	S	8038	$75.24	Disposed	20925	Direct
2021-09-02	Common Stock	S	5889	$76.14	Disposed	15036	Direct
2021-09-02	Common Stock	S	1474	$77.29	Disposed	13562	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-02	Stock option (right to buy)	$1.92	M	8989	Disposed	2026-05-23	Common Stock (8989.0)	Direct
2021-09-02	Stock option (right to buy)	$2.39	M	6412	Disposed	2028-05-09	Common Stock (6412.0)	Direct

Footnotes

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

F2: This transaction was executed in multiple trades at prices ranging from $74.59 to $75.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $75.60 to $76.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $76.70 to $77.63, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.

F6: 25% of the 12,305 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.